a close-up of a virus

R&D insights: Antibody-drug conjugates

Antibody-drug conjugates (ADCs) are a rapidly emerging class of cancer therapeutics that combine the targeting power of antibodies with the potent killing power of chemotherapy drugs. This targeted approach to cancer treatment has the potential to revolutionize the way cancer is treated, with over 100 ADCs in clinical trials and more than 15 approved by regulatory agencies worldwide.  For leaders of R&D, this idea in brief highlights key players, forces, and publication trends that enable better navigation of the opportunities ahead.

Download the Executive Summary

Related CAS Insights

Drug Discovery

A review of the global efforts on COVID-19 vaccine development

March 29, 2021

Read article
Drug Discovery

ACE2: Targeting a potentially important receptor in disease pathogenesis

December 15, 2022

Read article
Drug Discovery

ACS webinar on molecular glues and targeted protein degradation

October 12, 2022

Read article

Gain new perspectives for faster progress directly to your inbox.